Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New Data May Explain the Role of Sclerostin in Bone Formation

Lara C. Pullen, PhD  |  October 9, 2017

Humans and mice who have a deficiency in sclerostin present with a high-bone-mass phenotype. This finding has led pharmaceutical companies to develop several monoclonal antibodies that block sclerostin, with the hope that these antibodies will prove useful as treatments for osteoporosis. New data in mice reinforce the idea that the combination of sclerostin-neutralizing antibodies and physical activity may increase bone mass.

David Pflanz, a graduate student at Charite-Universitatsmedizin Berlin in Germany, and colleagues published the results of their research online Aug. 25 in Scientific Reports.1 The investigators focused their attention on mice engineered without the gene for sclerostin (i.e., Sost-knockout mice) to investigate the role of sclerostin in the structural adaptation of the tibia via surface modeling, remodeling and mechanical loading. They first examined if there were a difference in load transmission between Sost deficient mice and littermate controls.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“In this study, we examined whether in vivo tibial loading [for two weeks] could enhance bone formation and reduce bone resorption in young and adult female [Sost-knockout mice] and [littermate control] mice,” write the authors in their discussion. “We hypothesized that the bone formation and resorption response to mechanical loading is not affected by Sost deficiency, but is affected by skeletal maturation. We investigated changes in cortical bone morphology and the adaptive (re)modeling response using in vivo microCT imaging, registered microCT data as a 4D imaging biomarker of bone formation and resorption, and conventional 2D histomorphometry.”

The investigators found that, contrary to their hypothesis, the cortical adaptive response was enhanced in Sost-knockout mice compared with littermate control mice and that the knockout mice were more readily able to form cortical bone. Specifically, Sost-knockout mice had greater load-induced increases in periosteal bone formation rates and newly mineralized surface areas than did the littermate control mice. Moreover, when the researchers closely examined the dynamic microCT measures, they found the loaded limb had a significantly greater volume of newly formed bone than the control limb in both young and adult Sost-knockout mice. In contrast, only the young littermate control mice —not the old mice—had a significantly increased volume of newly formed bone in the loaded compared with the control limbs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers also found the ablation of the Wnt inhibitor Sost in the Sost-knockout mice led to increased expression of another Wnt inhibitor, Dkk1. When they looked more closely at the young Sost-knockout mice, they found that, at eight hours, the loaded limb had significantly decreased its expression of the Wnt inhibitor Dkk1 relative to the non-loaded limb.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bonebone formationOsteoporosissclerostin

Related Articles

    New Treatments Needed to Prevent Fractures in Osteoporosis

    June 1, 2014

    Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

    A Duet of Bone and the Immune System

    July 12, 2011

    Examining emerging perspectives in osteoimmunology

    2014 ACR/ARHP Annual Meeting: Alive and Growing

    February 1, 2015

    Bone disorders play role in development of osteoarthritis pain, progression

    A&R Abstracts – HMGB1

    August 1, 2011

    For Further Reading

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences